MODIFICATION
B -- Recovery: Solicitation for large scale, genome or exome or transciptome sequencing services using 2nd generation technologies complete with analysis
- Notice Date
- 11/23/2009
- Notice Type
- Modification/Amendment
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- ST101018
- Archive Date
- 1/30/2010
- Point of Contact
- Jeanne K Lewis, Phone: 301/228-4007, Shannon B Jackson, Phone: 301-228-4022
- E-Mail Address
-
lewisjk@mail.nih.gov, jacksonshannon@mail.nih.gov
(lewisjk@mail.nih.gov, jacksonshannon@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- A pre-proposal teleconference has been scheduled for December 4, 2009 at 10:00 am Eastern time. Organizations that will participate in this conference are requested to email the names of participants and number of lines they will be needing for the dial-in to jlewis@mail.nih.gov. The dial-in number is 1.800.366.7242, passcode is 84007. Cancer research has benefited during the last decade from the development of novel genomic analyses technologies. Knowledge of the human transcriptome has resulted in tools that allow for the interrogation of most of transcribed sequenced (protein or non-protein coding). The availability of the reference human genome resulted in technology that identified many of the genomic changes at the chromosomal region/region copy number level as well as the ability to determine loss of heterozygosity. Finally, the recent development of sequencing by synthesis or ligation methods and the instrumentation to support them is providing powerful and more precise approaches to characterize the transcriptome (gene expression changes, chimeric transcripts etc.), genome (deletions, amplifications, translocations) and epigenome (changes of methylation profiles) of tumors and at the same time as identifying the changes at the single nucleotide level, including base mutations, small deletions, insertions (in/dels), etc. The 2nd generation sequencing technologies are still improving and there is an expectation that the successful Contractors will implement them once they are validated in a pipeline environment. There has been some success in transforming discoveries of somatic aberrations, especially mutations, into clinical utility. The advances in characterization and sequencing using the new technologies allows a more rapid progress for these discoveries, therefore, NCI plans to bring the 2nd generation ("nextgen") sequencing technologies to bear on the TARGET Initiative. With this procurement we seek to obtain that 2nd generation sequencing capacity to sequence between 94-188 pediatric cancer cases each for 2-5 different cancer types to identify DNA mutations (such point mutation, deletions, insertions, etc.). Cancer Cases will be provided by through the TARGET pipeline. 2nd generation sequencing is defined as sequencing by synthesis or ligation with massively parallel throughput (examples can be found in Mardis, ER Trends in Gen 24:133, 2008). The scope of sequencing is either the exome (the minimum is either ~6,000 genes as defined and specified below or the complete exome), the complete transcriptome or whole genome for the same number cases. The aim is to utilize the new sequencing technologies in a highly cost-effective, high-throughput and efficient manner (i.e. Sanger sequencing does not meet this programs goals). The contractor is to provide their most current technology for the sequencing under the program. Therefore contractors may elect to sequence one of the below depending on what is required by their technology. The contract will be modified to reflect that technology and deliverables. The Contractor shall specify which technology is being proposed and what sequencing will be performed.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/ST101018/listing.html)
- Record
- SN02009792-W 20091125/091123235854-b33fd35337bf298a573a7a1cd97ee473 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |